Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.
$9.60 +0.26 (2.78%)
As of 08/12/2022 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.